GLP-1RAs May be Dangerous for Children

Guest, Dr. Dan Cooper

In opposition to the recent FDA approval, A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health.

superhumanradio.net